Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Total Valuation
Immunovant has a market cap or net worth of $2.68B. The enterprise value is $1.53B.
Market Cap$2.68B
Enterprise Value$1.53B
Share Statistics
Immunovant has 170,923,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding170,923,190
Owned by Insiders2.73%
Owned by Institutions24.73%
Financial Efficiency
Immunovant’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -62.06%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-62.06%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-1.14M
Employee Count362
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunovant is -6.26. Immunovant’s PEG ratio is -0.46.
PE Ratio-6.26
PS Ratio0.00
PB Ratio5.27
Price to Fair Value3.66
Price to FCF-10.13
Price to Operating Cash Flow-10.14
PEG Ratio-0.46
Income Statement
In the last 12 months, Immunovant had revenue of 0.00 and earned -413.84M in profits. Earnings per share was -2.73.
Revenue0.00
Gross Profit0.00
Operating Income-438.15M
Pretax Income-412.95M
Net Income-413.84M
EBITDA0.00
Earnings Per Share (EPS)-2.73
Cash Flow
In the last 12 months, operating cash flow was -375.87M and capital expenditures -759.00K, giving a free cash flow of -376.63M billion.
Operating Cash Flow-375.87M
Free Cash Flow-376.63M
Free Cash Flow per Share-2.20
Dividends & Yields
Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-41.57%
50-Day Moving Average14.96
200-Day Moving Average22.85
Relative Strength Index (RSI)52.17
Average Volume (3m)1.23M
Important Dates
Immunovant upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 29, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Immunovant as a current ratio of 11.16, with Debt / Equity ratio of 0.34%
Current Ratio11.16
Quick Ratio11.16
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunovant has paid 891.00K in taxes.
Income Tax891.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunovant EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -4.98.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-4.98
EV to Operating Cash Flow-4.99
Balance Sheet
Immunovant has $713.97M in cash and marketable securities with $98.00K in debt, giving a net cash position of -$713.87M billion.
Cash & Marketable Securities$713.97M
Total Debt$98.00K
Net Cash-$713.87M
Net Cash Per Share-$4.18
Tangible Book Value Per Share$4.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunovant is $45.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.00
Price Target Upside187.36% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-43.10%